Evidence map›Paper›PMID 18754025›Full record

ArticleLeukemia2008

Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia.

J E Castro, J D Sandoval-Sus, J Bole, L Rassenti, T J Kipps

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01191190 (A Phase II Study of Ofatumumab in Combination With High-dose Methylprednisolone in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia), which is not on this map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01191190 phase2completednot on this mapstarted 2010, after this paper: background citation

A Phase II Study of Ofatumumab in Combination With High-dose Methylprednisolone in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

TypeinterventionalSponsorJanuario Castro, M.D.Ran2010 to 2012Enrolled21ConditionsCLLArmsOfatumumab/HDMP
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013
    Trial
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Chronic lymphocytic leukaemia.Nature reviews. Disease primers · 2017
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. New strategies in chronic lymphocytic leukemia: shifting treatment paradigms.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

J E CastroMoores UCSD Cancer Center, La Jolla, CA 92093-0820, USA.
J D Sandoval-Sus
J Bole
L Rassenti
T J Kipps
Moores Cancer CenterLa Jolla Alcohol Research · US

Funding

Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GRIBBEN, JOHN G. · 2000 to 2016
$59.5M
Immunotherapy for Chronic Lymphocytic LeukemiaK08CA106605 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CASTRO, JANUARIO E · 2004 to 2008
$662k
NCI NIH HHS K08-CA106 605-01NCI NIH HHS P01 CA081534NCI NIH HHS P01-CA081534
6 · The paper itself

Abstract

We examined the clinical response of fludarabine-refractory CLL patients treated with high-dose methylprednisolone (HDMP) and rituximab. Fourteen patients were treated with three cycles of rituximab (375 mg/m(2) weekly for 4 weeks) in combination with HDMP (1 gm/m(2) daily for 5 days). All patients were refractory to fludarabine and 86% had high-risk disease by the modified Rai classification. In all, 79% of the patients had CLL cells that expressed ZAP-70 and three patients had poor prognostic cytogenetics. The overall response rate was 93% and the complete remission rate was 36%. The median time-to-progression was 15 months and the median time-to-next treatment was 22 months. Median survival has not been reached after a median follow up of 40 months. Four patients have died of progressive disease. Patients tolerated the treatment well and serious adverse events were rare. This allowed patients to receive all planned treatments on schedule with no dose modifications. All but one patient responded to treatment and the overall survival and time-to-progression were superior to those of other published salvage regimens.

Indexed as

Drug Resistance, NeoplasmSalvage TherapyAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Anti-Inflammatory AgentsAntineoplastic AgentsDisease-Free SurvivalDisease ProgressionDrug Therapy, CombinationFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellMaleAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Anti-Inflammatory AgentsAntineoplastic AgentsfludarabineMethylprednisoloneMyeloablative AgonistsRituximabVidarabine

Identifiers

PMID18754025
PMCPMC5289283
OpenAlexW2042521757

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.